Month: February 2026

Sumitomo Forestry Announces Strategic Combination with Tri Pointe Homes to Create a Leading U.S. Homebuilder

Written by Customer Service on February 13, 2026. Posted in Mergers And Acquisitions.

Supports expansion of affordable U.S. housing supply in addition to accelerating growth of Tri Pointe Homes’ high-quality homebuilding operations and providing U.S. homebuyers with a broader array of housing options Deepens Sumitomo Forestry’s U.S. investment with addition of Tri Pointe Homes’ more than 150 active communities and presence across 13 high-growth states Tri Pointe Homes stockholders to receive US$47.00 per share in all-cash transaction valued at approximately US$4.5 billion Represents approximately 29% premium to February 12 closing stock price, 42% premium to 90-day VWAP and exceeds all-time high closing stock price TOKYO and INCLINE VILLAGE, Nev., Feb. 13, 2026 (GLOBE NEWSWIRE) — Sumitomo Forestry Co., Ltd. (“Sumitomo Forestry”) (TSE: 1911) and Tri Pointe Homes, Inc. (“Tri Pointe Homes”) (NYSE: TPH), two companies...

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed here. Christopher Cargill, President and CEO of Nxera Pharma, commented: “2025 was a year of disciplined execution and strategic progress for Nxera, as we continued to build a more focused, resilient and scalable biopharmaceutical business with a growing commercial footprint in Japan and a maturing pipeline. “In doing so, we further strengthened our commercial foundations in Japan and the broader APAC region, with PIVLAZ® for the prevention of cerebral vasospasm after aneurysmal subarachnoid haemorrhage firmly established as the standard of care in Japan. We...

Huhtamäki Oyj’s Results January 1–December 31, 2025: Solid performance despite adverse currency impacts

Written by Customer Service on February 13, 2026. Posted in Public Companies.

HUHTAMÄKI OYJ FINANCIAL STATEMENT RELEASE 13.2.2026 AT 8:30 EET Huhtamäki Oyj’s Results January 1–December 31, 2025: Solid performance despite adverse currency impacts Q4 2025 in briefNet sales decreased 7% to EUR 980.5 million (EUR 1,058.7 million) Comparable net sales growth at Group level was -2% Reported EBIT was EUR 89.0 million (EUR 95.0 million); adjusted EBIT was EUR 103.2 million (EUR 110.3 million) including an adverse currency impact of EUR 4.3 million Reported EPS was EUR 0.53 (EUR 0.61); adjusted EPS was EUR 0.65 (EUR 0.68) The impact of currency movements on the Group’s net sales was EUR -58.9 million and EUR -4.3 million on EBITQ1-Q4 2025 in briefNet sales decreased 4% to EUR 3,960.2 million (EUR 4,126.3 million) Comparable net sales growth at Group level was -1% Reported EBIT was EUR 320.5 million (EUR 372.3 million);...

Aedifica NV/SA: 2025 annual results

Written by Customer Service on February 13, 2026. Posted in Public Companies.

Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding its 2025 annual results. Aedifica’s Exchange Offer on all Cofinimmo shares is now openCofinimmo shareholders are offered 1.185 new Aedifica shares for each share they tender The Initial Acceptance Period will close on 2 March 2026 (16:00 CET) Results of the Initial Acceptance Period are expected to be announced on 6 March, with settlement scheduled on 13 MarchRobust operational performance driving strong results above budgetEPRA Earnings* amounted to €244.8 million (+4% compared to 31 Dec. 2024) or €5.15/share Rental income increased to €361.0 million (+7% compared to 31 Dec. 2024) 2.7% increase in rental income on a like-for-like basis* over the year Weighted average...

Full-year 2025 results

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Full-year 2025 resultsRevenues of €22,465 million in 2025, up +1.7% Revenue growth at constant exchange rates* of +3.4% for the full year, and +10.6% in Q4 Bookings up +3.9% at constant exchange rates to €24.4 billion with a 1.08 book-to-bill Stable operating margin*, at 13.3% of revenues Net profit, Group share, of €1,601 million Basic earnings per share of €9.46, down -3.7% and normalized earnings per share of €12.95, up +5.8% Organic free cash flow* stable at €1.95 billion Proposed dividend of €3.40 per shareParis, February 13, 2026 – The Board of Directors of Capgemini SE, chaired by Paul Hermelin, convened on February 12, 2026 in Paris to review and adopt the accounts1...

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Written by Customer Service on February 13, 2026. Posted in Public Companies.

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1 Vanrafia received accelerated approval in U.S. and China for reduction of proteinuria in adults with IgAN in 2025; Novartis plans to submit for traditional approval in 20262Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p =...

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Written by Customer Service on February 13, 2026. Posted in Public Companies.

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from the Offering, before deducting offering expenses payable by the Company and discounts, will be approximately $20 million. Assuming full exercise by the underwriter of its option to purchase additional...

Alkane Resources Announces Record Operating & Record Financial Results for Q2 and H1 FY2026

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

PERTH, Australia, Feb. 12, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (“Alkane” or the “Company”) (ASX: ALK, OTC: ALKRY, TSX: ALK) is pleased to announce financial results for the six months ended 31 December 2025 (the “half” or “HY 2026”). The Company’s condensed and consolidated interim financial result for the half, together with the Appendix 4D and Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under Alkane’s profile on www.sedarplus.ca, on the Australian Securities Exchange (“ASX”) and on Alkane’s website at www.alkres.com. All currency references in this press release are in Australian dollars except as otherwise indicated. First Half 2026 Highlights: 1,2Record Revenues: Gold equivalent sales for the half year of 74,094 ounces generated revenues of $404 million at...

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

Written by Customer Service on February 13, 2026. Posted in Public Companies.

BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU). Currently, patient enrollment has been completed in the Phase III registrational clinical trial of soficitinib for the treatment of moderate to severe atopic dermatitis (AD), and in the Phase II clinical trial for the treatment of vitiligo. In addition, clinical trials of soficitinib for the treatment of psoriasis and nodular prurigo are also progressing rapidly. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Written by Customer Service on February 13, 2026. Posted in Public Companies.

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and...

Month: February 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals